NCT03830749View on ClinicalTrials.gov

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

March 31, 2023

Conditions

Immune Thrombocytopenia

Interventions

DRUG

Eltrombopag

Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone

Trial Locations (1)

Unknown

Humanity & Health Research Centre, Hong Kong

All Listed Sponsors

lead

Humanity & Health Medical Group Limited

OTHER

NCT03830749 - Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter